WITHDRAWN: 5-Fluorouracil-loaded iron/ethylcellulose (core/shell) nanoparticles for active targeting of cancer

References

• Arap W, Pasqualini R, Ruoslahti E. (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science, 279: 377–380.
   PubMed Web of Science ®Google Scholar
• Arias JL, Gallardo V, Linares-Molinero F, Delgado AV. (2006). Preparation and characterization of carbonyl iron/poly(butylcyanoacrylate) core/shell nanoparticles. J Colloid Interface Sci, 299: 599–607.
   PubMed Web of Science ®Google Scholar
• Arias JL, López-Viota M, Ruiz MA, López-Viota J, Delgado AV. (2007). Development of carbonyl iron/ethylcellulose core/shell nanoparticles for biomedical applications. Int J Pharm, 339: 237–245.
   PubMedGoogle Scholar
• Arias JL, Gallardo V, Ruiz MA, Delgado AV. (2008a). Magnetite/poly(alkylcyanoacrylate) (core/shell) nanoparticles as 5-Fluorouracil delivery systems for active targeting. Eur J Pharm Biopharm, 69: 54–63.
   PubMed Web of Science ®Google Scholar
• Arias JL, Linares-Molinero F, Gallardo V, Delgado AV. (2008b). Study of carbonyl iron/poly(butylcyanoacrylate) (core/shell) particles as anticancer drug delivery systems: loading and release properties. Eur J Pharm Sci, 33: 252–261.
   PubMed Web of Science ®Google Scholar
• Arias JL, Ruiz MA, López-Viota M, Delgado AV. (2008c). Poly(alkylcyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: a comparative study. Colloids Surf B: Biointerfaces, 62: 64–70.
   PubMed Web of Science ®Google Scholar
• Baccanari DP, Davis ST, Knick VC, Spector T. (1993). 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA, 90: 11064–11068.
   PubMed Web of Science ®Google Scholar
• Bertolini A, Fiumanò M, Muffatti A, Pedroncelli S, Doria A, Codazzi G, Giustiniani S, Scarinci A, Redaelli G. (1999). Acute cardiotoxicity due to 5-fluorouracil: an underestimated toxicity. Minerva Cardioangiol, 47: 269–274.
   PubMedGoogle Scholar
• Brasseur N, Brault D, Couvreur P. (1991). Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: carrier capacity and drug release. Int J Pharm, 70: 126–135.
   Google Scholar
• Brigger I, Morizet J, Laudani L, Aubert G, Appel M, Velasco V, Terrier-Lacombe MJ, Desmaële D, d’Angelo J, Couvreur P, Vassal G. (2004). Negative preclinical results with stealth® nanospheres-encapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release, 100: 29–40.
   PubMed Web of Science ®Google Scholar
• Chua-Anusorn W, Macey DJ, Webb J, de la Motte Hall P, St Pierre TG. (1999). Effects of prolonged iron loading in the rat using both parenteral and dietary routes. Biometals, 12: 103–113.
   PubMed Web of Science ®Google Scholar
• Cooke JWB, Bright R, Coleman MJ, Jenkins KP. (2001). Process research and development of a dihydropyrimidine dehydrogenase inactivator: large-scale preparation of enuracil using a sonogashira coupling. Organic Process Res & Develop, 5: 383–386.
   Web of Science ®Google Scholar
• DeMerlis CC, Schoneker DR, Borzelleca JF. (2005). A subchronic toxicity study in rats and genotoxicity tests with an aqueous ethylcellulose dispersion. Food Chem Toxicol, 43: 1355–1364.
   PubMed Web of Science ®Google Scholar
• Dubernet C, Rouland JC, Benoit JP. (1990). Comparative study of two ethylcellulose forms (raw material and microspheres) carried out through thermal analysis. Int J Pharm, 64: 99–107.
   Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev, 56: 1177–1192.
   PubMed Web of Science ®Google Scholar
• Gang J, Park SB, Hyung W, Choi EH, Wen J, Kim HS, Shul YG, Haam S, Song SY. (2007). Magnetic poly ϵ-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model. J Drug Target, 15: 445–453.
   PubMed Web of Science ®Google Scholar
• Grattard N, Pernin M, Marty B, Roudaut G, Champion D, LeMeste M. (2002). Study of release kinetics of small and high molecular weight substances dispersed into spray-dried ethylcellulose microspheres. J Control Release, 84: 125–135.
   PubMed Web of Science ®Google Scholar
• Greig NH, Genka S, Rapoport SI. (1990). Delivery of vital drugs to the brain for the treatment of brain tumors. J Control Release, 11: 61–78.
   Web of Science ®Google Scholar
• Ibrahim A, Couvreur P, Roland M, Speiser P. (1983). New magnetic drug carrier. J Pharm Pharmacol, 35: 59–61.
   PubMed Web of Science ®Google Scholar
• Kato T, Sato K, Sasaki R, Kakinuma H, Moriyama M. (1996). Targeted cancer chemotherapy with arterial microcapsule chemoembolization: review of 1013 patients. Cancer Chemother Pharmacol, 37: 289–296.
   PubMed Web of Science ®Google Scholar
• Kelmann RG, Kuminek G, Teixeira HF, Koester LS. (2007). Carbamazepine parenteral nanoemulsions prepared by spontaneous emulsification process. Int J Pharm, 342: 231–239.
   PubMed Web of Science ®Google Scholar
• Llovet MI, Egea MA, Valero J, Alsina MA, García ML, Chauvet A. (1995). Methotrexate-loaded nanoparticles: analysis of drug content and study of the matrix structure. Drug Dev Ind Pharm, 21: 1761–1771.
   Web of Science ®Google Scholar
• Lu YJ, Low PS. (2002). Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev, 54: 675–693.
   PubMed Web of Science ®Google Scholar
• Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Doerken B, Herrmann F, Guertler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke AJ, Ohlendorf D, Huhnt W, Huhn D. (1996a). Clinical experiences with magnetic drug targeting: a phase I study with 4’-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res, 56: 4686–4693.
   PubMed Web of Science ®Google Scholar
• Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D. (1996b). Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res, 56: 4694–4701.
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, Zhao X, Qin J. (2006). Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release, 114: 53–59.
   PubMed Web of Science ®Google Scholar
• Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul, 41: 189–207.
   PubMedGoogle Scholar
• Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release, 65: 271–284.
   PubMed Web of Science ®Google Scholar
• McCarron PA, Woolfson AD, Keating SM. (2000). Sustained release of 5-fluorouracil from polymeric nanoparticles. J Pharm Pharmacol, 52: 1451–1459.
   PubMed Web of Science ®Google Scholar
• Meers P. (2001). Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev, 53: 265–272.
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. (2001). Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev, 53: 283–318.
   PubMed Web of Science ®Google Scholar
• Needham D, Dewhirst MW. (2001). The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev, 53: 285–305.
   PubMed Web of Science ®Google Scholar
• Novotný L, Farghali H, Janků I, Beránek J. (1989). The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum. Cancer Chemother Pharmacol, 24: 238–242.
   PubMed Web of Science ®Google Scholar
• Okon E, Pouliquen D, Okon P, Kovaleva ZV, Stepanova TP, Lavit SG, Kudryavtsev BN, Jallet P. (1994). Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical study. Lab Invest, 71: 895–903.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulus D, Benz CC. (2002). Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin Cancer Res, 8: 1172–1181.
   PubMed Web of Science ®Google Scholar
• Rapoport N. (2004). Combined cancer therapy by micellar- encapsulated drug and ultrasound. Int J Pharm, 277: 155–162.
   PubMed Web of Science ®Google Scholar
• Shum P, Kim JM, Thompson DH. (2001). Phototriggering of liposomal drug delivery systems. Adv Drug Deliv Rev, 53: 273–284.
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70: 1–20.
   PubMed Web of Science ®Google Scholar
• Stolnik S, Illum L, Davis SS. (1995). Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 16: 195–214.
   Web of Science ®Google Scholar
• Ulbrich K, Šubr V. (2004). Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev, 56: 1023–1050.
   PubMed Web of Science ®Google Scholar
• Vanderhoff JW, El-Aasser MS, Ugelstad J. (1979, December 4). Polymer Emulsification Process. U.S. Patent No. 4,177,177.
   Google Scholar
• Whittaker P, Ali SF, Imam SF, Dunkel VC. (2002). Acute toxicity of carbonyl iron and sodium iron EDTA compared with ferrous sulfate in young rats. Regul Toxicol Pharmacol, 36: 280–286.
   PubMed Web of Science ®Google Scholar
• Zhang N, Yin Y, Xu SJ, Chen WS. (2008). 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules, 13: 1551–1569.
   PubMed Web of Science ®Google Scholar
• Zinutti C, Kedzierewicz F, Hoffamn M, Benoit JP, Maincent P. (1996). Influence of the casting solvent on the physico-chemical properties of 5-fluorouracil loaded microspheres. Int J Pharm, 133: 97–105.
   Web of Science ®Google Scholar